Literature DB >> 9476481

Western blot analysis of the immune response to Candida albicans antigens in 391 long-term intensive care patients.

C Weis1, R Kappe, H G Sonntag.   

Abstract

The aim of this study was to determine, using Western blot, the prevalence of anti-Candida albicans antibodies in long-term intensive care patients and to characterize specific immune responses that may only occur in patients with invasive candidosis. A total of 1751 serum samples from 391 patients of a German multicentre study, which was designed to determine the incidence of systemic candidosis, was examined. Significantly enhanced antibody production against specific antigens was observed in several subgroups of patients, i.e. those with underlying disease of the pancreas (29 kDa, P = 0.006), cholecystolithiasis (47 kDa, P = 0.029), gastrointestinal tract disease (47 kDa, P = 0.03), steroid therapy (58 kDa, P = 0.02), thrush (58 kDa, P = 0.032), urogenital infection (58 kDa, P = 0.034), Candida antigen titre > or = 1:4 (58 kDa, P = 0.002) and positive fungal culture (36 kDa, P = 0.033) and those who had died (36 kDa, P = 0.011). In contrast to earlier publications, an immune response against the 29 and 47 kDa antigens was relatively common among long-term intensive care patients (37% and 70% antibody positive respectively). A single antigen that provided satisfactory sensitivity and specificity for the discrimination between fungal infection and no fungal infection or between superficial and invasive fungal infection was not identified in this study.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9476481     DOI: 10.1111/j.1439-0507.1997.tb00207.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  3 in total

1.  Simple and rapid detection of Candida albicans DNA in serum by PCR for diagnosis of invasive candidiasis.

Authors:  R Wahyuningsih; H J Freisleben; H G Sonntag; P Schnitzler
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

2.  Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90.

Authors:  Ruth C Matthews; Gordon Rigg; Samantha Hodgetts; Tracey Carter; Caroline Chapman; Carl Gregory; Chris Illidge; James Burnie
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

Review 3.  Human monoclonal antibody-based therapy in the treatment of invasive candidiasis.

Authors:  Francesca Bugli; Margherita Cacaci; Cecilia Martini; Riccardo Torelli; Brunella Posteraro; Maurizio Sanguinetti; Francesco Paroni Sterbini
Journal:  Clin Dev Immunol       Date:  2013-06-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.